PEG CCS 13
Alternative Names: PEG-CCS-13Latest Information Update: 30 Mar 2023
At a glance
- Originator D5 Pharma
- Class Anti-inflammatories; DNA
- Mechanism of Action CD200R1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation